Signal from the log
Life Biosciences
80 M$ · Series D and later · United States · Biotech
Biotech de Boston qui reprogramme partiellement l'épigénome de cellules vieillies vers un état plus jeune, au moyen de trois facteurs de transcription. Son candidat ER-100 est en phase 1 contre le glaucome et la neuropathie optique ischémique antérieure. Aucun investisseur n'est nommé dans le communiqué.
Spotted
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 80 M$
- Stage
- Series D and later
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
What is missing before publishing
- No fund is publicly named. It is the first condition of the selection bar: without a named investor there is no round to tell.
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.